We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.87B
AUM Growth
+$435M
Cap. Flow
+$144M
Cap. Flow %
3.71%
Top 10 Hldgs %
35.18%
Holding
133
New
4
Increased
60
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$39.2M
2
BPMC
Blueprint Medicines
BPMC
+$35.9M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$21.8M
4
WST icon
West Pharmaceutical
WST
+$21.2M
5
GOSS icon
Gossamer Bio
GOSS
+$19.7M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$64.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.5M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$15.4M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$14.2M
5
EPZM
Epizyme, Inc
EPZM
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.71%
2 Consumer Staples 0.91%
3 Industrials 0.67%
4 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYPH
101
Cypherpunk Technologies Inc
CYPH
$72.2M
$3.22M 0.08%
365,985
+690
+0.2% +$8.38K
FULC icon
102
Fulcrum Therapeutics
FULC
$282M
$3.11M 0.08%
384,590
– –
BLSA
103
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.1M 0.08%
309,000
– –
ALT icon
104
Altimmune
ALT
$591M
$2.85M 0.07%
+223,255
New +$3.3M
THRX
105
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.54M 0.07%
437,329
– –
ADAP
106
DELISTED
Adaptimmune Therapeutics
ADAP
$2.53M 0.07%
2,357,544
– –
ICVX
107
DELISTED
Icosavax, Inc. Common Stock
ICVX
$2.47M 0.06%
781,000
+19,443
+3% +$122K
FATE icon
108
Fate Therapeutics
FATE
$316M
$2.46M 0.06%
110,000
– –
SPRB
109
Spruce Biosciences
SPRB
$129M
$2.22M 0.06%
21,636
– –
JYAC
110
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.06M 0.05%
206,200
– –
ELVN icon
111
Enliven Therapeutics
ELVN
$4.23B
$1.92M 0.05%
210,601
– –
SYRE icon
112
Spyre Therapeutics
SYRE
$8.91B
$1.8M 0.05%
136,556
+13,675
+11% +$169K
SPRO icon
113
Spero Therapeutics
SPRO
$70.6M
$1.54M 0.04%
770,710
– –
VINC
114
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.53M 0.04%
55,429
+14,719
+36% +$423K
TPST icon
115
Tempest Therapeutics
TPST
$16.9M
$1.43M 0.04%
63,358
– –
TLPH icon
116
Talphera
TLPH
$73.2M
$1.32M 0.03%
316,460
– –
BHVN icon
117
Biohaven
BHVN
$2.12B
$1.05M 0.03%
+171,272
New +$1.24M
EPIX
118
DELISTED
ESSA Pharma
EPIX
$955K 0.02%
524,944
– –
CGEN icon
119
Compugen
CGEN
$229M
$848K 0.02%
1,289,990
– –
BCEL
120
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$726K 0.02%
462,530
– –
APLT
121
DELISTED
Applied Therapeutics
APLT
$653K 0.02%
701,680
– –
PHAS
122
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$479K 0.01%
2,719,074
-55,795
-2% -$56.9K
ALT icon
123
CALL
Altimmune
ALT
$591M
$428K 0.01%
+33,500
New +$495K
NUVB.WS
124
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$27K ﹤0.01%
134,028
– –
PRLD icon
125
Prelude Therapeutics
PRLD
$389M
– –
-368,959
Closed -$1.93M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rock Springs Capital Management held 133 positions worth $3.87B, up 13% from $3.44B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management deployed $144M of net new capital in Q3 2022, opening 4 new positions and adding to 60 existing holdings. Its largest new stake was Gossamer Bio: 1,586,962 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Shockwave Medical, Inc. Common Stock, an estimated $15.4M trimmed.

  • Rock Springs Capital Management's largest Q3 2022 buy was Gossamer Bio: 1,586,962 shares worth $19M.
  • Rock Springs Capital Management added most to Immunocore in Q3 2022, an estimated $39.2M increase.
  • Rock Springs Capital Management's biggest Q3 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $64.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.87B portfolio in Q3 2022.
  • Rock Springs Capital Management opened 4 new positions and closed 5 in Q3 2022.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $3.87B.

Based on Rock Springs Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.